ORKA
HEALTHCAREOruka Therapeutics, Inc.
AI Insight
What's Moving ORKA Today?
No stock-specific AI insight has been generated for ORKA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$10.83$91.00
$83.66
Fundamentals
Market Cap$5.1B
P/E Ratio—
EPS$-1.93
Dividend Yield—
Dividend / Share—
ROE-27.3%
Profit Margin—
Debt / Equity—
Trading
Volume212K
Avg Volume (10D)—
Shares Outstanding60.3M
ORKA News
23 articles- Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·Jun 12, 2026
- Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to TradeYahoo Finance·Jun 10, 2026
- An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 MillionThe Motley Fool·May 31, 2026
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2026
- Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh FundingYahoo Finance·May 15, 2026
- Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%Motley Fool·May 13, 2026
- Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer CompanyMotley Fool·May 13, 2026
- Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% RallyMotley Fool·May 13, 2026
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 13, 2026
- Oruka Therapeutics Announces Closing of Merger with ARCAGlobeNewswire·May 13, 2026
- Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan StanleyYahoo Finance·May 12, 2026
- A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?Motley Fool·May 11, 2026
- H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue OutlookYahoo Finance·May 11, 2026
- Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)Yahoo Finance·May 10, 2026
- Why Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis BreakthroughYahoo Finance·May 10, 2026
- Halozyme and Oruka sign agreement for Hypercon technologyPharmaceutical-technology·May 7, 2026
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyYahoo Finance·May 6, 2026
- Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001Yahoo Finance·Apr 30, 2026
- Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public OfferingGlobeNewswire Inc.·Apr 28, 2026
- Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis DosingMarketbeat·Apr 28, 2026
- Oruka Therapeutics (ORKA) Hits Record High on Stellar Clinical Trial ResultYahoo Finance·Apr 28, 2026
- Oruka Therapeutics Announces Proposed $500 Million Underwritten Public OfferingBenzinga·Apr 27, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
All 23 articles loaded
Price Data
Open$81.99
Previous Close$83.40
Day High$84.38
Day Low$80.42
52 Week High$91.00
52 Week Low$10.83
52-Week Range
$10.83$91.00
$83.66
Fundamentals
Market Cap$5.1B
P/E Ratio—
EPS$-1.93
Dividend Yield—
Dividend / Share—
ROE-27.3%
Profit Margin—
Debt / Equity—
Trading
Volume212K
Avg Volume (10D)—
Shares Outstanding60.3M
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a biotechnology company.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—